In a more recent cohort study, rheumatoid arthritis patients on either methotrexate or tumour necrosis factor alpha (TNF-α) inhibitors, were twice as likely to develop bladder cancer as the general population (Setoguchi et al, 2006). Here, TNF is linked to rheumatoid arthritis.